Developments in diagnosis and treatment of essential thrombocythemia

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–2405.
   PubMed Web of Science ®Google Scholar
• Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and meta-analysis. Am J Hematol. 2014;89:581–587.
   PubMed Web of Science ®Google Scholar
• Moulard O, Mehta J, Fryzek J, et al. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union. Eur J Haematol. 2014;92:289–297.
   PubMed Web of Science ®Google Scholar
• Stein BL, Gotlib J, Arcasoy M, et al. Historical views, conventional approaches, and evolving management strategies for myeloproliferative neoplasms. J Nat Compr Cancer Netw. 2015;13:424–434.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Viero P, Finazzi G, et al. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol. 1990;8:556–562.
   PubMed Web of Science ®Google Scholar
• Fenaux P, Simon M, Caulier MT, et al. Clinical course of essential thrombocythemia in 147 cases. Cancer. 1990;66:549–556.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Fonseca R, Pereira DL, et al. A long-term retrospective study of young women with essential thrombocythemia. Mayo Clin Proc. 2001;76:22–28.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Thiele J, Passamonti F, et al. Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients. Blood. 2011;117:5857–5859.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management. Am J Hematol. 2017;92:94–108.
   PubMed Web of Science ®Google Scholar
• Dueck AC, Geyer HL, Kiladjian -J-J, et al. Myeloproliferative (MPN) symptom burden response thresholds: assessment of MPN-SAF TSS quartiles as potential markers of symptom response. Blood. 2013;122:4067.
   Google Scholar
• Johansson P, Mesa R, Scherber R, et al. Association between quality of life and clinical parameters in patients with myeloproliferative neoplasms. Leuk Lymphoma. 2012;53:441–444.
   PubMed Web of Science ®Google Scholar
• Murphy H SI, Rosenthal D, Laszlo J. Essential thrombocythemia: an interim report from the polycythemia vera study group. SeminHematol. 1986;23:177–182.
   Web of Science ®Google Scholar
• Kralovics R, Passamonti F, Buser AS, et al. A gain-of function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352:1779–1790.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Elena C, Schnittger S, et al. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood. 2011;117:2813–2816.
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T, et al. Mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108:3472–3476.
   PubMed Web of Science ®Google Scholar
• Klampfl T, Gisslinger H, Harutyunyan AS, et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369:2379–2390.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Passamonti F, et al. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study. J Clin Oncol. 2011;29:3179–3184.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Schmitt-Graeff A, et al. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients. Am J Hematol. 2002;70:283–291.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Jeryczynski G, Gisslinger B, et al. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria. Leukemia. 2016;30:1126–1132.
   PubMed Web of Science ®Google Scholar
• Rumi E, Cazzola M. How I treat essential thrombocythemia. Blood. 2016;128:2403–2414.
   PubMed Web of Science ®Google Scholar
• Pietra D, Rumi E, Ferretti VV, et al. Differential clinical effects of different mutation subtypes in CALR mutant myeloproliferative neoplasms. Leukemia. 2016;30:431–438.
   PubMed Web of Science ®Google Scholar
• Tortolani PJ, Johnston JA, Bacon CM, et al. Thrombopoietin induces tyrosine phosphorylation and activation of the Janus kinase, JAK2. Blood. 1995;85:3444–3451.
   PubMed Web of Science ®Google Scholar
• Araki M, Yang Y, Masubuchi N, et al. Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms. Blood. 2016;127:1307–1316.
   PubMed Web of Science ®Google Scholar
• Chachoua I, Pecquet C, El-Khoury M, et al. Thrombopoietin receptor activation by myeloproliferative neoplasm associated calreticulin mutants. Blood. 2016;127:1325–1335.
   PubMed Web of Science ®Google Scholar
• Pecquet C, Balligand T, Chachoua I, et al. Secreted mutant calreticulins as rogue cytokines trigger thrombopoietin receptor activation specifically in CALR mutated cells: perspectives for MPN therapy. ASH Meeting 2018, San Diego (CA). Oral presentation.
   Google Scholar
• Mansier O, Luque Paz D, Ianotto JC, et al. Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study. Am J Hematol. 2018;93:E84–E86.
   PubMed Web of Science ®Google Scholar
• Barbui T, Tefferi A, Vannucchi AM, et al. Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European Leukemia Net. Leukemia. 2018;32:1057–1069.
   PubMed Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127:325–332.
   PubMed Web of Science ®Google Scholar
• Cabagnols X, Favale F, Pasquier F, et al. Presence of atypical thrombopoietin receptor (MPL) mutations in triple-negative essential thrombocythemia patients. Blood. 2016;127:333–342.
   PubMed Web of Science ®Google Scholar
• Kittur J, Knudson RA, Lasho TL, et al. Clinical correlates of JAK2V617F allele burden in essential thrombocythemia. Cancer. 2007;109:2279–2284.
   PubMed Web of Science ®Google Scholar
• Cheung B, Radia D, Pantelidis P, et al. The presence of the JAK2 V617F mutation is associated with a higher haemoglobin and increased risk of thrombosis in essential thrombocythaemia. Br J Haematol. 2006;132:244–245.
   PubMed Web of Science ®Google Scholar
• Zhang S, Qiu H, Fischer BS, et al. JAK2 V617F patients with essential thrombocythemia present with clinical features of polycythemia vera. Leuk Lymphoma. 2008;49:696–699.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, Scott LM, Buck G, et al. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet. 2005;366:1945–1953.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Ferretti V, et al. CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes. Blood. 2014;123:1544–1551.
   PubMed Web of Science ®Google Scholar
• Rotunno G, Mannarelli C, Guglielmelli P, et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood. 2014;123:1552–1555.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood. 2008;112:844–847.
   PubMed Web of Science ®Google Scholar
• Rumi E, Pietra D, Guglielmelli P, et al. Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood. 2013;121:4388–4395.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke C, et al. Targeted next-generation sequencing in polycythemia vera and essential thrombocythemia. Blood. 2015;126:354.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Guglielmelli P, et al. Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Adv. 2016;1:21–30.
   PubMed Web of Science ®Google Scholar
• Barbui T, Thiele J, Gisslinger H, et al. The 2016 revision of WHO classification of myeloproliferative neoplasms: clinical and molecular advances. Blood Rev. 2016;30:453–459.
   PubMed Web of Science ®Google Scholar
• Kvasnicka HM, Orazi A, Thiele J, et al. European Leukemia Net study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. Am J Hematol. 2017;92:1062–1067.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Ancochea A, García M, et al. WHO-histological criteria for myeloproliferative neoplasms: reproducibility, diagnostic accuracy and correlation with gene mutations and clinical outcomes. Br J Haematol. 2014;166:911–919.
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Müllauer L, et al. Essential thrombocythemia versus early primary myelofibrosis: a multicenter study to validate the WHO classification. Blood. 2011;117:5710–5718.
   PubMed Web of Science ®Google Scholar
• Mudireddy M, Barraco D, Hanson CA, et al. The prognostic relevance of serum lactate dehydrogenase and mild bone marrow reticulin fibrosis in essential thrombocythemia. Am J Hematol. 2017;92:454–459.
   PubMed Web of Science ®Google Scholar
• Jeryczynski G, Thiele J, Gisslinger B, et al. Pre-fibrotic/early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease. Am J Hematol. 2017;92:885–891.
   PubMed Web of Science ®Google Scholar
• Rumi E, Boveri E, Bellini M, et al. Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria. Oncotarget. 2017;8:101735–101744.
   PubMedGoogle Scholar
• Palandri F, Latagliata R, Polverelli N, et al. Mutations and long term outcome of 217 young patients with essential thrombocythemia or early primary myelofibrosis. Leukemia. 2015;29:1344–1349.
   PubMed Web of Science ®Google Scholar
• Gangat N, Tefferi A, Thanarajasingam G, et al. Cytogenetic abnormalities in essential thrombocythemia: prevalence and prognostic significance. Eur J Haematol. 2009;83:17–21.
   PubMed Web of Science ®Google Scholar
• Sessarego M, Defferrari R, Dejana AM, et al. Cytogenetic analysis in essential thrombocythemia at diagnosis and at transformation. A 12-year study. Cancer Genet Cytogenet. 1989;43:57–65.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Antonioli E, Guglielmelli P, et al. Clinical profile of homozygous JAK2 617VF mutation in patients with polycythemia vera or essential thrombocythemia. Blood. 2017;110:840–846.
   Google Scholar
• Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med. 2004;117:755–761.
   PubMed Web of Science ®Google Scholar
• Dentali F, Ageno W, Rumi E, et al. Cerebral venous thrombosis and myeloproliferative neoplasms: results from two large databases. Thromb Res. 2014;134:41–43.
   PubMed Web of Science ®Google Scholar
• Chait Y, Condat B, Cazals-Hatem D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol. 2005;129:553–560.
   PubMed Web of Science ®Google Scholar
• Dentali F, Squizzato A, Brivio L, et al. JAK2V617F mutation for the early diagnosis of Ph myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis. Blood. 2009;113:5617–5623.
   PubMed Web of Science ®Google Scholar
• Roques M, Park JH, Minello A, et al. Detection of the CALR mutation in the diagnosis of splanchnic vein thrombosis. Br J Haematol. 2015;169:601–603.
   PubMed Web of Science ®Google Scholar
• Barbui T, Barosi G, Birgegard G, et al.; European Leukemia Net. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol. 2011;29:761–770.
   PubMed Web of Science ®Google Scholar
• Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23:2224–2232.
   PubMed Web of Science ®Google Scholar
• Ruggeri M, Finazzi G, Tosetto A, et al. No treatment for low-risk thrombocythaemia: results from a prospective study. Br J Haematol. 1998;103:772–777.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G, Carobbio A, et al. Development and validation of an international prognostic score of thrombosis in World Health Organization essential thrombocythemia (IPSET-thrombosis). Blood. 2012;120:5128–5133.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Cervantes F, Bellosillo B, et al. Essential thrombocythemia in young individuals: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients. Leukemia. 2007;21:1218–1223.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Carobbio A, Guglielmelli P, et al. Calreticulin mutation does not modify the IPSET score for predicting the risk of thrombosis among 1150 patients with essential thrombocythemia. Blood. 2014;124:2611–2612.
   PubMed Web of Science ®Google Scholar
• Barbui T, Vannucchi AM, Buxhofer-Ausch V, et al. Practice-relevant revision of IPSET thrombosis based on 1019 patients with WHO-defined essential thrombocythemia. Blood Cancer J. 2015;5:e369.
   PubMed Web of Science ®Google Scholar
• Haider M, Gangat N, Lasho T, et al. Validation of the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET thrombosis) in 585 mayo clinic patients. Am J Hematol. 2016;91:390–394.
   PubMed Web of Science ®Google Scholar
• Wong RSM, Cheng C-K, Chan NPH, et al. JAK2 V617F mutation is associated with increased risk of thrombosis in Chinese patients with essential thrombocythaemia. Br J Haematol. 2008;141:902–904.
   PubMed Web of Science ®Google Scholar
• Torregrosa JM, Ferrer-Marin F, Lozano ML, et al. Impaired leucocyte activation is underlining the lower thrombotic risk of essential thrombocythaemia patients with CALR mutations as compared with those with the JAK2 mutation. Br J Haematol. 2016;172:813–815.
   PubMed Web of Science ®Google Scholar
• Guglielmelli P, Gangat N, Coltro G et al. Mutations and thrombosis in essential thrombocythemia and polycythemia vera: mayo-careggi alliance study. ASH meeting 2018, San Diego (CA). Abstract 3040.
   Google Scholar
• Tefferi A, Vannucchi AM, Barbui T. Current treatment algorithm in essential thrombocytemia. Blood Cancer J. 2018;8:2.
   PubMed Web of Science ®Google Scholar
• Gangat N, Wassie EA, Lasho TL, et al. Mutations and thrombosis in essential thrombocythemia: prognostic interaction with age and thrombosis history. Eur J Haematol. 2015;94:31–36.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Antonioli E, et al. Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia. Blood. 2008;112:3135–3137.
   PubMed Web of Science ®Google Scholar
• Palandri F, Polverelli N, Catani L, et al. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol. 2011;90:933–938.
   PubMed Web of Science ®Google Scholar
• Campbell PJ, MacLean C, Beer PA, et al. Correlation of blood counts with vascular complications in essential thrombocythemia: analysis of the prospective PT1 cohort. Blood. 2012;120:1409–1411.
   PubMed Web of Science ®Google Scholar
• Lim Y, Lee JO, Kim SH, et al. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden. Thromb Res. 2015;135:846–851.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E, et al. Influence of the JAK2 V617F mutation and inherited thrombophilia on the thrombotic risk among patients with essential thrombocythemia. Haematologica. 2009;94:733–737.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Carobbio A, Thiele J, et al. Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria. Leukemia. 2012;26:716–719.
   PubMed Web of Science ®Google Scholar
• Casini A, Fontana P, Tp L. Thrombotic complications of myeloproliferative neoplasms: risk assessment and risk-guided management. J Thromb Haemost. 2013;11:1215–1227.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2005;128:275–290.
   PubMed Web of Science ®Google Scholar
• Budde U, van Genderen  PJ. Acquired von Willebrand disease in patients with high platelet counts. Semin Thromb Hemost. 1997;23:425–431.
   PubMed Web of Science ®Google Scholar
• Federici AB, Rand JH, Bucciarelli P, et al. Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost. 2000;84:345–349.
   PubMed Web of Science ®Google Scholar
• Kreher S, Ochsenreither S, Trappe RU, et al. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (OGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.). Ann Hematol. 2014;3:1953–1963.
   Google Scholar
• Michiels JJ, Van Genderen PJJ, Lindemans J, et al. Erythromelalgic, thrombotic and hemorrhagic manifestations in 50 cases of thrombocythemia. Leuk Lymphoma. 1996;22:47–56.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cazzola M. Cytoreductive therapy for patients with essential thrombocythemia at high risk of thromboembolic complications. The difficult choice of the optimal drug. Haematologica. 2004;89:1284.
   PubMed Web of Science ®Google Scholar
• Godfrey AL, Campbell PJ, MacLean C, et al. Hydroxycarbamide plus aspirin versus aspirin alone in patients with essential thrombocythemia age 40 to 59 years without high-risk features. J Clin Oncol. 2018;36:3361–3369.
   Web of Science ®Google Scholar
• Barosi G, Besses C, Birgegard G, et al. A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group. Leukemia. 2007;21:277–280.
   PubMed Web of Science ®Google Scholar
• Palandri F, Catani L, Testoni N, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. Am J Hematol. 2009;84:215–220.
   PubMed Web of Science ®Google Scholar
• Carobbio A, Finazzi G, Antonioli E, et al. Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European Leukemia Net criteria. Blood. 2010;116:1051–1055.
   PubMed Web of Science ®Google Scholar
• Hernandez-Boluda JC, Pereira A, Cervantes F, et al. Clinical evaluation of the European Leukemia Net response criteria in patients with essential thrombocythemia treated with anagrelide. Ann Hematol. 2013;92:771–775.
   PubMed Web of Science ®Google Scholar
• Barosi G, Tefferi A, Barbui T, et al. Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients? Leukemia. 2012;26:1148–1149.
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood. 2013;121:4778–4781.
   PubMed Web of Science ®Google Scholar
• Cortelazzo S, Finazzi G, Ruggeri M, et al. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med. 1995;332:1132–1137.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med. 2005;353:33–45.
   PubMed Web of Science ®Google Scholar
• Gisslinger H, Gotic M, Holowiecki J, et al. Anagrelide compared with hydroxyurea in WHO-classified essential thrombocythemia: the ANAHYDRET Study, a randomized controlled trial. Blood. 2013;121:1720–1728.
   PubMed Web of Science ®Google Scholar
• Mascarenhas J, Kosiorek H, Prchal JT et al. Results of the Myeloproliferative Neoplasm-Research Consortim (MPN-RC) 112 randomized trial of pegylated interferon alfa-2° versus hydroxyurea therapy for the treatment of high risk polycythemia vera and high risk essential thrombocytemia. ASH meeting 2018, San Diego (CA). Abstract 577.
   Google Scholar
• Cassinat B, Verger E, Kiladjian JJ. Interferon alfa therapy in CALR-mutated essential thrombocythemia. N Engl J Med. 2014;371:188–189.
   PubMed Web of Science ®Google Scholar
• Verger E, Cassinat B, Chauveau A, et al. Clinical and molecular response to interferon-a therapy in essential thrombocythemia patients with CALR mutations. Blood. 2015;126:2585–2591.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Abdel-Wahab O, Manshouri T, et al. Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon a-2a. Blood. 2013;122:893–901.
   PubMed Web of Science ®Google Scholar
• Antonioli E, Guglielmelli P, Pieri L, et al. Hydroxyurea-related toxicity in 3,411 patients with Ph’-negative MPN. Am J Hematol. 2012;87:552–554.
   PubMed Web of Science ®Google Scholar
• Bjorkholm M, Derolf AR, Hultcrantz M, et al. Treatment-related risk factors for transformation to acute myeloid leukemia and myelodysplastic syndromes in myeloproliferative neoplasms. J Clin Oncol. 2011;29:2410–2415.
   PubMed Web of Science ®Google Scholar
• Birgegård G, Folkvaljon F, Garmo H, et al. Leukemic transformation and second cancers in 3649 patients with high-risk essential thrombocythemia in the EXELS study. Leuk Res. 2018;74:105–109.
   PubMed Web of Science ®Google Scholar
• Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27:5418–5424.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Giraudier S, Cassinat B. Interferon alpha for the therapy of myeloproliferative neoplasms: targeting the malignant clone. Leukemia. 2016;30:776–781.
   PubMed Web of Science ®Google Scholar
• Kiladjian JJ, Mesa RA, Hoffman R. The renaissance of interferon therapy for the treatment of myeloid malignancies. Blood. 2011;117:4706–4715.
   PubMed Web of Science ®Google Scholar
• Sleijfer S, Bannink M, Van Gool AR, et al. Side effects of interferon-alpha therapy. Pharm World Sci. 2005;27:423–431.
   PubMed Web of Science ®Google Scholar
• Mela Osorio MJ, Ferrari L, Goette NP, et al. Long term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. Eur J Haematol. 2016;96:435–442.
   PubMed Web of Science ®Google Scholar
• Baerlocher GM, Oppliger Leibundgut E, Ottmann OG, et al. Telomerase inhibitor imetelstat in patients with essential thrombocythemia. N Engl J Med. 2015;373:920–928.
   PubMed Web of Science ®Google Scholar
• Rambaldi A, Dellacasa CM, Finazzi G, et al. A pilot study of the histone-deacetylase inhibitor givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms. Br J Haematol. 2010;150:446–455.
   PubMed Web of Science ®Google Scholar
• Andersen CL, McMullin MF, Ejerblad E, et al. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. Br J Haematol. 2013;162:498–508.
   PubMed Web of Science ®Google Scholar
• Verstovsek S, Passamonti F, Rambaldi A, et al. Ruxolitinib for essential thrombocythemia refractory to or intolerant of hydroxyurea: long-term phase 2 study results. Blood. 2017;130:1768–1771.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Mead AJ, Panchal A, et al. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood. 2017;130:1889–1897.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350:114–124.
   PubMed Web of Science ®Google Scholar
• Chu DK, Hillis CM, Leong DP, et al. Benefits and risks of antithrombotic therapy in essential thrombocythemia: a systematic review. Ann Intern Med. 2017;167:170–180.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larrán A, Pereira A, Arellano-Rodrigo E, et al. Cytoreduction plus low-dose aspirin versus cytoreduction alone as primary prophylaxis of thrombosis in patients with high-risk essential thrombocythaemia: an observational study. Br J Haematol. 2013;161:865–871.
   PubMed Web of Science ®Google Scholar
• Alvarez-Larran A, Pereira A, Guglielmelli P, et al. Antiplatelet therapy versus observation in low-risk essential thrombocythemia with CALR mutation. Haematologica. 2016;101:926–931.
   PubMed Web of Science ®Google Scholar
• Dillinger JG, Sideris G, Henry P, et al. Twice daily aspirin to improve biological aspirin efficacy in patients with essential thrombocythemia. Thromb Res. 2012;129:91–94.
   PubMed Web of Science ®Google Scholar
• Harrison CN, Bareford D, Butt N, et al. Guideline for investigation and management of adults and children presenting with a thrombocytosis. Br J Haematol. 2010;149:352–375.
   PubMed Web of Science ®Google Scholar
• Vannucchi AM, Barbui T, Cervantes F, et al. Philadelphia chromosome negative chronic myeloproliferative neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26:v85–v99.
   PubMed Web of Science ®Google Scholar
• Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149:315–352.
   PubMed Web of Science ®Google Scholar
• De Stefano V, Za T, Rossi E, et al. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments. Haematologica. 2008;93:372–380.
   PubMed Web of Science ®Google Scholar
• Appelmann I, Kreher S, Parmentier S, et al. Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the hemostasis working party of the german society of hematology and medical oncology (DGHO) and the society of thrombosis and hemostasis research (GTH). Ann Hematol. 2016;95:707–718.
   PubMed Web of Science ®Google Scholar
• Wright CA, Tefferi A. A single institutional experience with 43 pregnancies in essential thrombocythemia. Eur J Haematol. 2001;66:152–159.
   PubMed Web of Science ®Google Scholar
• Lavi N, Brenner B, Avivi I. Management of pregnant women with myeloproliferative neoplasms. Thromb Res. 2013;131:S11–S13.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Randi ML, Rumi E, et al. Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation. Blood. 2007;110:485–489.
   PubMed Web of Science ®Google Scholar
• Alimam S, Bewley S, Chappell LC, et al. Pregnancy outcomes in myeloproliferative neoplasms: UK prospective cohort study. Br J Haematol. 2016;175:31–36.
   PubMed Web of Science ®Google Scholar
• Harrison CN. Pregnancy and its management in the Philadelphia negative myeloproliferative diseases. Br J Haematol. 2005;129:293–306.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G Myeloproliferative disease in pregnancy and other management issues. ASH EducProg Book. 2006;2006:246–252.
   Google Scholar
• Gangat N, Wolanskyj AP, Schwager S, et al. Predictors of pregnancy outcome in essential thrombocythemia: a single institution study of 63 pregnancies. Eur J Haematol. 2009;82:350–353.
   PubMed Web of Science ®Google Scholar
• Rumi E, Bertozzi I, Casetti IC, et al. Impact of mutational status on pregnancy outcome in patients with essential thrombocytemia. Haematologica. 2015;100:e443–e445.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Randi ML, et al. Aspirin in pregnant patients with essential thrombocythemia: a retrospective analysis of 129 pregnancies. J Thromb Haemost. 2010;8:411–413.
   PubMed Web of Science ®Google Scholar
• Randi ML, Bertozzi I, Rumi E, et al. Pregnancy complications predict thrombotic events in young women with essential thrombocythemia. Am J Hematol. 2014;89:306–309.
   PubMed Web of Science ®Google Scholar
• Datta P, Rewers-Felkins K, Kallem RR, et al. Transfer of low dose aspirin into human milk. J Hum Lact. 2017;33:296–299.
   PubMed Web of Science ®Google Scholar
• Garozzo G, Disca S, Fidone C, et al. Azoospermia in a patient with sickle cell disease treated with hydroxyurea. Haematologica. 2000;85:1216–1218.
   PubMed Web of Science ®Google Scholar
• Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood. 1999;94:1480–1482.
   PubMed Web of Science ®Google Scholar
• Ding J, Komatsu H, Wakita A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103:4198–4200.
   PubMed Web of Science ®Google Scholar
• Rumi E, Passamonti F, Pietra D, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer. 2006;107:2206–2211.
   PubMed Web of Science ®Google Scholar
• Bellanne-Chantelot C, Chaumarel I, Labopin M, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood. 2006;108:346–352.
   PubMed Web of Science ®Google Scholar
• Rumi E, Harutyunyan AS, Pietra D, et al. CALR exon 9 mutations are somatically acquired events in familial cases of essential thrombocythemia or primary myelofibrosis. Blood. 2014;123:2416–2419.
   PubMed Web of Science ®Google Scholar
• Maffioli M, Genoni A, Caramazza D, et al. Looking for CALR mutations in familial myeloproliferative neoplasms. Leukemia. 2014;28:1357–1360.
   PubMed Web of Science ®Google Scholar
• Olcaydu D, Rumi E, Harutyunyan A, et al. The role of the JAK2 GGCC haplotype and the TET2 gene in familial myeloproliferative neoplasms. Hematologica. 2011;96:367–374.
   PubMed Web of Science ®Google Scholar
• Hinds DA, Barnholt KE, Mesa RA, et al. Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms. Blood. 2016;128:1121–1128.
   PubMed Web of Science ®Google Scholar
• Rumi E, Passamonti F, Della Porta MG, et al. Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation. J Clin Oncol. 2007;25:5630–5635.
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Lund SH, Landgren O, et al. Survival in patients with familial and sporadic myeloproliferative neoplasms. Blood. 2015;125:3665–3666.
   PubMed Web of Science ®Google Scholar
• Wolanskyj AP, Schwager SM, McClure RF, et al. Essential thrombocythemia beyond the first decade: life expectancy, long-term complication rates, and prognostic factors. Mayo Clin Proc. 2006;81:159–166.
   PubMed Web of Science ®Google Scholar
• Barosi G, Mesa RA, Thiele J. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia. 2008 Feb;22:437–438.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Larson DR, et al. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood. 2014;124:2507–2513.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Mora B, Giorgino T, et al. Driver mutations’ effect in secondary myelofibrosis: an international multicenter study based on 781 patients. Leukemia. 2017;31:970–973.
   PubMed Web of Science ®Google Scholar
• Mora B, Giorgino T, Guglielmelli P, et al. Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. Leuk Res. 2018;69:100–102.
   PubMed Web of Science ®Google Scholar
• Abdulkarim K, Ridell B, Johansson P, et al. The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera. Eur J Haematol. 2011;86:148–155.
   PubMed Web of Science ®Google Scholar
• Mora B, Giorgino T, Guglielmelli P, et al. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018;103:e392–e394.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Giorgino T, Mora B, et al. A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis. Leukemia. 2017;31:2726–2731.
   PubMed Web of Science ®Google Scholar
• Masarova L, Bose P, Pemmaraju N, et al. Validation of the Myelofibrosis Secondary to PV and ET-Prognostic Model in Patients with Post-Polycythemia Vera and Post-Essential Thrombocythemia Myelofibrosis: MD Anderson Cancer Center. ASH meeting 2017, San Diego (CA). Abstract 4205.
   Google Scholar
• Hernández-Boluda JC, Pereira A, Correa JG, et al. Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis. Leukemia. 2018;32:553–555.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocyemia: a study on 605 patients. Haematologica. 2008;93:1645–1651.
   PubMed Web of Science ®Google Scholar
• Gangat N, Wolanskyj AP, McClure RF, et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia. 2006;21:270–276.
   PubMed Web of Science ®Google Scholar
• Hernandez-Boluda JC, Alvarez-Larran A, Gomez M, et al. Clinical evaluation of the European Leukaemia Net criteria for clinicohaematological response and resistance/intolerance to hydroxycarbamide in essential thrombocythaemia. Br J Haematol. 2011;152:81–88.
   PubMed Web of Science ®Google Scholar
• Passamonti F, Thiele J, Girodon F, et al. A prognostic model to predict survival in 867 World Health Organization–defined essential thrombocythemia at diagnosis: a study by the international working group on myelofibrosis research and treatment. Blood. 2012;120:1197–1201.
   PubMed Web of Science ®Google Scholar
• Elala YC, Lasho T, Gangat N, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91:503–506.
   PubMed Web of Science ®Google Scholar
• Haider M, Elala YC, Gangat N, et al. MPL mutations and palpable splenomegaly are independent risk factors for fibrotic progression in essential thrombocythemia. Blood Cancer J. 2016;6:e487.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Guglielmelli P, Lasho TL, et al. Mutation-Enhanced International Prognostic Systems for Essential Thrombocythemia (MIPSS-ET) and Polycythemia Vera (MIPSS-PV). ASH meeting 2018, San Diego (CA). Abstract 578.
   Google Scholar
• Passamonti F, Rumi E, Arcaini L, et al. Leukemic transformation of polycythemia vera: a single center study of 23 patients. Cancer. 2005;104:1032–1036.
   PubMed Web of Science ®Google Scholar